CA2867489A1 - Procedes et composition permettant le sequencage d'acides nucleiques modifies - Google Patents

Procedes et composition permettant le sequencage d'acides nucleiques modifies Download PDF

Info

Publication number: CA2867489A1
Authority: CA; Canada
Prior art keywords: sequence; data; nucleic acid; sequencing; nucleic acids
Prior art date: 2012-03-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2867489A

Other languages

English (en)

Inventor

Jonas Korlach

Stephen Turner

Tyson A. Clark

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pacific Biosciences of California Inc

Original Assignee

Pacific Biosciences of California Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-30

Filing date

2013-03-18

Publication date

2013-10-03

2013-03-18 Application filed by Pacific Biosciences of California Inc filed Critical Pacific Biosciences of California Inc

2013-10-03 Publication of CA2867489A1 publication Critical patent/CA2867489A1/fr

Status Abandoned legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 410
102000039446 nucleic acids Human genes 0.000 title claims abstract description 379
108020004707 nucleic acids Proteins 0.000 title claims abstract description 379
238000000034 method Methods 0.000 title claims abstract description 274
238000012163 sequencing technique Methods 0.000 title claims abstract description 271
239000000203 mixture Substances 0.000 title claims abstract description 57
238000012986 modification Methods 0.000 claims abstract description 391
230000004048 modification Effects 0.000 claims abstract description 387
125000003729 nucleotide group Chemical group 0.000 claims abstract description 118
239000003795 chemical substances by application Substances 0.000 claims abstract description 42
238000006243 chemical reaction Methods 0.000 claims description 212
108020004414 DNA Proteins 0.000 claims description 151
210000004027 cell Anatomy 0.000 claims description 129
239000000523 sample Substances 0.000 claims description 124
108090000623 proteins and genes Proteins 0.000 claims description 107
230000011987 methylation Effects 0.000 claims description 74
238000007069 methylation reaction Methods 0.000 claims description 74
239000002773 nucleotide Substances 0.000 claims description 63
210000000349 chromosome Anatomy 0.000 claims description 60
206010028980 Neoplasm Diseases 0.000 claims description 59
230000000295 complement effect Effects 0.000 claims description 44
230000014509 gene expression Effects 0.000 claims description 43
230000000694 effects Effects 0.000 claims description 40
239000012634 fragment Substances 0.000 claims description 37
238000010348 incorporation Methods 0.000 claims description 37
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 29
108010033040 Histones Proteins 0.000 claims description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
210000001519 tissue Anatomy 0.000 claims description 28
230000027455 binding Effects 0.000 claims description 27
230000004049 epigenetic modification Effects 0.000 claims description 26
201000011510 cancer Diseases 0.000 claims description 23
108020004999 messenger RNA Proteins 0.000 claims description 21
244000005700 microbiome Species 0.000 claims description 21
230000008859 change Effects 0.000 claims description 20
239000011541 reaction mixture Substances 0.000 claims description 20
102000006947 Histones Human genes 0.000 claims description 19
230000001973 epigenetic effect Effects 0.000 claims description 19
230000008774 maternal effect Effects 0.000 claims description 19
230000002759 chromosomal effect Effects 0.000 claims description 18
201000010099 disease Diseases 0.000 claims description 18
230000001580 bacterial effect Effects 0.000 claims description 17
210000001766 X chromosome Anatomy 0.000 claims description 15
239000011230 binding agent Substances 0.000 claims description 15
239000008280 blood Substances 0.000 claims description 15
210000004369 blood Anatomy 0.000 claims description 15
108091008109 Pseudogenes Proteins 0.000 claims description 14
102000057361 Pseudogenes Human genes 0.000 claims description 14
230000009870 specific binding Effects 0.000 claims description 14
102000054766 genetic haplotypes Human genes 0.000 claims description 13
230000001605 fetal effect Effects 0.000 claims description 12
230000008672 reprogramming Effects 0.000 claims description 12
230000001594 aberrant effect Effects 0.000 claims description 11
239000012472 biological sample Substances 0.000 claims description 11
230000018109 developmental process Effects 0.000 claims description 11
230000002068 genetic effect Effects 0.000 claims description 11
230000004044 response Effects 0.000 claims description 11
210000003578 bacterial chromosome Anatomy 0.000 claims description 10
238000011161 development Methods 0.000 claims description 10
230000035772 mutation Effects 0.000 claims description 10
230000010076 replication Effects 0.000 claims description 10
108091028733 RNTP Proteins 0.000 claims description 9
241000894006 Bacteria Species 0.000 claims description 8
230000004913 activation Effects 0.000 claims description 8
238000000137 annealing Methods 0.000 claims description 8
244000052769 pathogen Species 0.000 claims description 8
230000003252 repetitive effect Effects 0.000 claims description 8
238000004113 cell culture Methods 0.000 claims description 7
230000007423 decrease Effects 0.000 claims description 7
230000002779 inactivation Effects 0.000 claims description 7
230000001717 pathogenic effect Effects 0.000 claims description 7
108091023040 Transcription factor Proteins 0.000 claims description 6
102000040945 Transcription factor Human genes 0.000 claims description 6
230000003612 virological effect Effects 0.000 claims description 6
238000007672 fourth generation sequencing Methods 0.000 claims description 5
230000033607 mismatch repair Effects 0.000 claims description 5
210000000130 stem cell Anatomy 0.000 claims description 5
210000002308 embryonic cell Anatomy 0.000 claims description 4
230000002538 fungal effect Effects 0.000 claims description 4
238000007031 hydroxymethylation reaction Methods 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
230000037353 metabolic pathway Effects 0.000 claims description 4
231100000765 toxin Toxicity 0.000 claims description 4
239000003053 toxin Substances 0.000 claims description 4
241000233866 Fungi Species 0.000 claims description 3
208000002720 Malnutrition Diseases 0.000 claims description 3
238000001574 biopsy Methods 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 3
239000001963 growth medium Substances 0.000 claims description 3
230000001071 malnutrition Effects 0.000 claims description 3
235000000824 malnutrition Nutrition 0.000 claims description 3
208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
206010036790 Productive cough Diseases 0.000 claims description 2
230000000112 colonic effect Effects 0.000 claims description 2
230000017858 demethylation Effects 0.000 claims description 2
238000010520 demethylation reaction Methods 0.000 claims description 2
239000003596 drug target Substances 0.000 claims description 2
208000016361 genetic disease Diseases 0.000 claims description 2
208000019622 heart disease Diseases 0.000 claims description 2
210000000056 organ Anatomy 0.000 claims description 2
230000003071 parasitic effect Effects 0.000 claims description 2
230000035755 proliferation Effects 0.000 claims description 2
208000024794 sputum Diseases 0.000 claims description 2
210000003802 sputum Anatomy 0.000 claims description 2
210000004881 tumor cell Anatomy 0.000 claims description 2
210000002700 urine Anatomy 0.000 claims description 2
244000000010 microbial pathogen Species 0.000 claims 1
238000012512 characterization method Methods 0.000 abstract description 3
238000001514 detection method Methods 0.000 description 90
230000003287 optical effect Effects 0.000 description 59
102000004190 Enzymes Human genes 0.000 description 54
108090000790 Enzymes Proteins 0.000 description 54
108060004795 Methyltransferase Proteins 0.000 description 47
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 46
102000040430 polynucleotide Human genes 0.000 description 46
108091033319 polynucleotide Proteins 0.000 description 46
239000002157 polynucleotide Substances 0.000 description 46
238000004458 analytical method Methods 0.000 description 42
238000005516 engineering process Methods 0.000 description 42
102000004169 proteins and genes Human genes 0.000 description 36
102000016397 Methyltransferase Human genes 0.000 description 35
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 33
239000000758 substrate Substances 0.000 description 30
238000011282 treatment Methods 0.000 description 27
238000003786 synthesis reaction Methods 0.000 description 26
108091028043 Nucleic acid sequence Proteins 0.000 description 23
230000015572 biosynthetic process Effects 0.000 description 21
238000013507 mapping Methods 0.000 description 20
239000013612 plasmid Substances 0.000 description 20
230000006378 damage Effects 0.000 description 18
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 17
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 17
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 17
238000012545 processing Methods 0.000 description 16
239000007787 solid Substances 0.000 description 15
108700028369 Alleles Proteins 0.000 description 14
230000003321 amplification Effects 0.000 description 14
-1 e.g. Chemical class 0.000 description 14
238000012544 monitoring process Methods 0.000 description 14
238000003199 nucleic acid amplification method Methods 0.000 description 14
230000008569 process Effects 0.000 description 14
108010077544 Chromatin Proteins 0.000 description 13
102000055027 Protein Methyltransferases Human genes 0.000 description 13
108700040121 Protein Methyltransferases Proteins 0.000 description 13
238000004422 calculation algorithm Methods 0.000 description 13
210000003483 chromatin Anatomy 0.000 description 13
239000002609 medium Substances 0.000 description 13
239000011148 porous material Substances 0.000 description 13
230000001419 dependent effect Effects 0.000 description 12
239000013598 vector Substances 0.000 description 12
238000007792 addition Methods 0.000 description 11
230000008901 benefit Effects 0.000 description 11
229940104302 cytosine Drugs 0.000 description 11
208000035475 disorder Diseases 0.000 description 11
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 11
230000008775 paternal effect Effects 0.000 description 11
239000000126 substance Substances 0.000 description 11
RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 10
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
230000006607 hypermethylation Effects 0.000 description 10
230000003902 lesion Effects 0.000 description 10
230000009466 transformation Effects 0.000 description 10
108010044289 DNA Restriction-Modification Enzymes Proteins 0.000 description 9
230000005778 DNA damage Effects 0.000 description 9
231100000277 DNA damage Toxicity 0.000 description 9
230000003993 interaction Effects 0.000 description 9
230000007246 mechanism Effects 0.000 description 9
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 9
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 8
102000006465 DNA Restriction-Modification Enzymes Human genes 0.000 description 8
238000001369 bisulfite sequencing Methods 0.000 description 8
230000005284 excitation Effects 0.000 description 8
238000011068 loading method Methods 0.000 description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
208000035657 Abasia Diseases 0.000 description 7
229930024421 Adenine Natural products 0.000 description 7
102000000340 Glucosyltransferases Human genes 0.000 description 7
108010055629 Glucosyltransferases Proteins 0.000 description 7
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 7
102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 7
101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 7
201000010769 Prader-Willi syndrome Diseases 0.000 description 7
229960000643 adenine Drugs 0.000 description 7
239000003153 chemical reaction reagent Substances 0.000 description 7
238000012217 deletion Methods 0.000 description 7
230000037430 deletion Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
238000002372 labelling Methods 0.000 description 7
230000037361 pathway Effects 0.000 description 7
239000000047 product Substances 0.000 description 7
230000005855 radiation Effects 0.000 description 7
239000000376 reactant Substances 0.000 description 7
238000011160 research Methods 0.000 description 7
238000007619 statistical method Methods 0.000 description 7
230000002103 transcriptional effect Effects 0.000 description 7
238000013519 translation Methods 0.000 description 7
208000009575 Angelman syndrome Diseases 0.000 description 6
108091029523 CpG island Proteins 0.000 description 6
229910019142 PO4 Inorganic materials 0.000 description 6
238000013459 approach Methods 0.000 description 6
238000003491 array Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000006399 behavior Effects 0.000 description 6
239000000470 constituent Substances 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
238000006116 polymerization reaction Methods 0.000 description 6
238000012216 screening Methods 0.000 description 6
CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 description 5
108091035707 Consensus sequence Proteins 0.000 description 5
230000007067 DNA methylation Effects 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
241000282412 Homo Species 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
238000007385 chemical modification Methods 0.000 description 5
230000007613 environmental effect Effects 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000010452 phosphate Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
229940035893 uracil Drugs 0.000 description 5
102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
108091093088 Amplicon Proteins 0.000 description 4
108091028732 Concatemer Proteins 0.000 description 4
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
108020001738 DNA Glycosylase Proteins 0.000 description 4
102000028381 DNA glycosylase Human genes 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
108010022894 Euchromatin Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
108091093078 Pyrimidine dimer Proteins 0.000 description 4
101710188297 Trehalose synthase/amylase TreS Proteins 0.000 description 4
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000033228 biological regulation Effects 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000008995 epigenetic change Effects 0.000 description 4
210000000632 euchromatin Anatomy 0.000 description 4
239000008103 glucose Substances 0.000 description 4
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000005286 illumination Methods 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000003446 ligand Substances 0.000 description 4
125000005647 linker group Chemical group 0.000 description 4
239000000463 material Substances 0.000 description 4
238000002493 microarray Methods 0.000 description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
238000000746 purification Methods 0.000 description 4
150000003220 pyrenes Chemical class 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
238000005096 rolling process Methods 0.000 description 4
238000005070 sampling Methods 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 3
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 3
241000193755 Bacillus cereus Species 0.000 description 3
239000002126 C01EB10 - Adenosine Substances 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
108060002716 Exonuclease Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
108700039691 Genetic Promoter Regions Proteins 0.000 description 3
108010034791 Heterochromatin Proteins 0.000 description 3
102100039869 Histone H2B type F-S Human genes 0.000 description 3
101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 3
101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 3
229930010555 Inosine Natural products 0.000 description 3
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 3
230000021736 acetylation Effects 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
229960005305 adenosine Drugs 0.000 description 3
238000001261 affinity purification Methods 0.000 description 3
230000032683 aging Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000008236 biological pathway Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000022131 cell cycle Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000011109 contamination Methods 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
238000004163 cytometry Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000005549 deoxyribonucleoside Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
102000013165 exonuclease Human genes 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
210000004458 heterochromatin Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000003100 immobilizing effect Effects 0.000 description 3
229960003786 inosine Drugs 0.000 description 3
238000011835 investigation Methods 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000002777 nucleoside Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000007918 pathogenicity Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
238000012546 transfer Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
RIFDKYBNWNPCQK-IOSLPCCCSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-3-methylpurin-9-yl)oxolane-3,4-diol Chemical compound C1=2N(C)C=NC(=N)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RIFDKYBNWNPCQK-IOSLPCCCSA-N 0.000 description 2
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 2
ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 2
SUDBRAWXUGTELR-HPFNVAMJSA-N 5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1h-pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCC1=CNC(=O)NC1=O SUDBRAWXUGTELR-HPFNVAMJSA-N 0.000 description 2
OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 2
RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
241000589875 Campylobacter jejuni Species 0.000 description 2
241001078573 Campylobacter jejuni subsp. jejuni 81-176 Species 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 description 2
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
230000030914 DNA methylation on adenine Effects 0.000 description 2
230000030933 DNA methylation on cytosine Effects 0.000 description 2
230000008836 DNA modification Effects 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
108700034637 EC 3.2.-.- Proteins 0.000 description 2
241000771616 Escherichia coli ER2796 Species 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
208000020584 Polyploidy Diseases 0.000 description 2
229930185560 Pseudouridine Natural products 0.000 description 2
PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
108091033400 Small nucleolar RNA SNORD116 Proteins 0.000 description 2
241000993896 Vibrio breoganii 1C10 Species 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
JCZSFCLRSONYLH-UHFFFAOYSA-N Wyosine Natural products N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3C1OC(CO)C(O)C1O JCZSFCLRSONYLH-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000011324 bead Substances 0.000 description 2
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
230000031018 biological processes and functions Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
238000010804 cDNA synthesis Methods 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000032671 dosage compensation Effects 0.000 description 2
231100000049 endocrine disruptor Toxicity 0.000 description 2
239000000598 endocrine disruptor Substances 0.000 description 2
210000000750 endocrine system Anatomy 0.000 description 2
231100000317 environmental toxin Toxicity 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
230000036541 health Effects 0.000 description 2
230000003862 health status Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000000415 inactivating effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000012164 methylation sequencing Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
238000002887 multiple sequence alignment Methods 0.000 description 2
108091027963 non-coding RNA Proteins 0.000 description 2
102000042567 non-coding RNA Human genes 0.000 description 2
238000001668 nucleic acid synthesis Methods 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
150000004713 phosphodiesters Chemical group 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
208000006155 precocious puberty Diseases 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000013635 pyrimidine dimer Substances 0.000 description 2
QQXQGKSPIMGUIZ-AEZJAUAXSA-N queuosine Chemical compound C1=2C(=O)NC(N)=NC=2N([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=C1CN[C@H]1C=C[C@H](O)[C@@H]1O QQXQGKSPIMGUIZ-AEZJAUAXSA-N 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
239000002342 ribonucleoside Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000011451 sequencing strategy Methods 0.000 description 2
210000003765 sex chromosome Anatomy 0.000 description 2
238000004557 single molecule detection Methods 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
238000007671 third-generation sequencing Methods 0.000 description 2
230000005945 translocation Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
150000003852 triazoles Chemical class 0.000 description 2
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
229940045145 uridine Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
JCZSFCLRSONYLH-QYVSTXNMSA-N wyosin Chemical compound N=1C(C)=CN(C(C=2N=C3)=O)C=1N(C)C=2N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JCZSFCLRSONYLH-QYVSTXNMSA-N 0.000 description 2
MXYRZDAGKTVQIL-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methyloxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MXYRZDAGKTVQIL-IOSLPCCCSA-N 0.000 description 1
SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
PZJOKSNRXMHAJS-UHFFFAOYSA-N 2,6-bis(ethylsulfanylmethyl)pyridine Chemical compound CCSCC1=CC=CC(CSCC)=N1 PZJOKSNRXMHAJS-UHFFFAOYSA-N 0.000 description 1
YKUFMYSNUQLIQS-UHFFFAOYSA-N 2-amino-5-methyl-1h-pyrimidin-6-one Chemical compound CC1=CNC(N)=NC1=O YKUFMYSNUQLIQS-UHFFFAOYSA-N 0.000 description 1
COHVJBUINVIGOI-UHFFFAOYSA-N 4-amino-4-methyl-1,3-dihydropyrimidin-2-one Chemical compound CC1(N)NC(=O)NC=C1 COHVJBUINVIGOI-UHFFFAOYSA-N 0.000 description 1
JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
OFJNVANOCZHTMW-UHFFFAOYSA-N 5-hydroxyuracil Chemical compound OC1=CNC(=O)NC1=O OFJNVANOCZHTMW-UHFFFAOYSA-N 0.000 description 1
NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 description 1
HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241001135756 Alphaproteobacteria Species 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000219195 Arabidopsis thaliana Species 0.000 description 1
101100443354 Arabidopsis thaliana DME gene Proteins 0.000 description 1
101100331657 Arabidopsis thaliana DML2 gene Proteins 0.000 description 1
101100331658 Arabidopsis thaliana DML3 gene Proteins 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
208000020706 Autistic disease Diseases 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000322342 Bacillus phage M2 Species 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
208000035049 Blood-Borne Infections Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
241000047960 Chromohalobacter salexigens Species 0.000 description 1
241001110715 Chromohalobacter salexigens DSM 3043 Species 0.000 description 1
208000037051 Chromosomal Instability Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108091029430 CpG site Proteins 0.000 description 1
102000004480 Cyclin-Dependent Kinase Inhibitor p57 Human genes 0.000 description 1
108010017222 Cyclin-Dependent Kinase Inhibitor p57 Proteins 0.000 description 1
102100026846 Cytidine deaminase Human genes 0.000 description 1
108010031325 Cytidine deaminase Proteins 0.000 description 1
108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108091028709 DNA adenine Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
108091006089 DNA- and RNA-binding proteins Proteins 0.000 description 1
102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 description 1
108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000001914 Fragile X syndrome Diseases 0.000 description 1
108020000949 Fungal DNA Proteins 0.000 description 1
241000192128 Gammaproteobacteria Species 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
241001135751 Geobacter metallireducens Species 0.000 description 1
241000134679 Geobacter metallireducens GS-15 Species 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010025076 Holoenzymes Proteins 0.000 description 1
101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
101100155061 Homo sapiens UBE3A gene Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241000289419 Metatheria Species 0.000 description 1
108700011259 MicroRNAs Proteins 0.000 description 1
108091092878 Microsatellite Proteins 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
241000221961 Neurospora crassa Species 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
101150054516 PRD1 gene Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
241000702072 Podoviridae Species 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
102000017033 Porins Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
101100459905 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NCP1 gene Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000701518 Salmonella virus PRD1 Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
108020004688 Small Nuclear RNA Proteins 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
102000042773 Small Nucleolar RNA Human genes 0.000 description 1
108020003224 Small Nucleolar RNA Proteins 0.000 description 1
102100034803 Small nuclear ribonucleoprotein-associated protein N Human genes 0.000 description 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
102000008579 Transposases Human genes 0.000 description 1
108010020764 Transposases Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
101150045356 UBE3A gene Proteins 0.000 description 1
208000031655 Uniparental Disomy Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
108700029631 X-Linked Genes Proteins 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000003450 affinity purification method Methods 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
125000002355 alkine group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
BBEAQIROQSPTKN-UHFFFAOYSA-N antipyrene Natural products C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
230000000712 assembly Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
DQEPMTIXHXSFOR-UHFFFAOYSA-N benzo[a]pyrene diol epoxide I Chemical compound C1=C2C(C3OC3C(C3O)O)=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 DQEPMTIXHXSFOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000007698 birth defect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003200 chromosome mapping Methods 0.000 description 1
230000024321 chromosome segregation Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000007621 cluster analysis Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000003927 comet assay Methods 0.000 description 1
231100000170 comet assay Toxicity 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000004624 confocal microscopy Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000013480 data collection Methods 0.000 description 1
238000013501 data transformation Methods 0.000 description 1
230000006196 deacetylation Effects 0.000 description 1
238000003381 deacetylation reaction Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
WJJMNDUMQPNECX-UHFFFAOYSA-L dipicolinate(2-) Chemical compound [O-]C(=O)C1=CC=CC(C([O-])=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-L 0.000 description 1
238000009509 drug development Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000005518 electrochemistry Effects 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
125000001240 enamine group Chemical group 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007608 epigenetic mechanism Effects 0.000 description 1
230000006565 epigenetic process Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000000695 excitation spectrum Methods 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
230000006543 gametophyte development Effects 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
238000012226 gene silencing method Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
238000012165 high-throughput sequencing Methods 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003317 industrial substance Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000003064 k means clustering Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
SNSSXAGSGDLKFZ-UHFFFAOYSA-N lead;1h-pyrimidine-2,4-dione Chemical compound [Pb].OC=1C=CNC(=O)N=1 SNSSXAGSGDLKFZ-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000004731 long QT syndrome Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000017156 mRNA modification Effects 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000010311 mammalian development Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000007726 management method Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000009245 menopause Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000002679 microRNA Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000004377 microelectronic Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
208000012268 mitochondrial disease Diseases 0.000 description 1
238000006011 modification reaction Methods 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000002086 nanomaterial Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000006855 networking Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003955 neuronal function Effects 0.000 description 1
230000001293 nucleolytic effect Effects 0.000 description 1
235000021231 nutrient uptake Nutrition 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
239000013307 optical fiber Substances 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000010287 polarization Effects 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
206010036601 premature menopause Diseases 0.000 description 1
238000003793 prenatal diagnosis Methods 0.000 description 1
238000009609 prenatal screening Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000009993 protective function Effects 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical compound OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
UUVCRNTVNKTNRK-UHFFFAOYSA-N pyridine-2,6-dicarboxamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=N1 UUVCRNTVNKTNRK-UHFFFAOYSA-N 0.000 description 1
239000002096 quantum dot Substances 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000010223 real-time analysis Methods 0.000 description 1
238000011897 real-time detection Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003290 ribose derivatives Chemical class 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
WHALSQRTWNBBCV-UHFFFAOYSA-N s-aminosulfanylthiohydroxylamine Chemical compound NSSN WHALSQRTWNBBCV-UHFFFAOYSA-N 0.000 description 1
238000001963 scanning near-field photolithography Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000020509 sex determination Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229910000077 silane Inorganic materials 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
108010039827 snRNP Core Proteins Proteins 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
238000001447 template-directed synthesis Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
231100000462 teratogen Toxicity 0.000 description 1
239000003439 teratogenic agent Substances 0.000 description 1
230000002381 testicular Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
GUKSGXOLJNWRLZ-UHFFFAOYSA-N thymine glycol Chemical compound CC1(O)C(O)NC(=O)NC1=O GUKSGXOLJNWRLZ-UHFFFAOYSA-N 0.000 description 1
238000000204 total internal reflection microscopy Methods 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
238000012085 transcriptional profiling Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
230000001018 virulence Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA2867489A 2012-03-30 2013-03-18 Procedes et composition permettant le sequencage d'acides nucleiques modifies Abandoned CA2867489A1 (fr)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261617999P	2012-03-30	2012-03-30
US61/617,999		2012-03-30
US201261721206P	2012-11-01	2012-11-01
US201261721339P	2012-11-01	2012-11-01
US201361789354P	2013-03-15	2013-03-15
US201361799237P	2013-03-15	2013-03-15
PCT/US2013/032816 WO2013148400A1 (fr)	2012-03-30	2013-03-18	Procédés et composition permettant le séquençage d'acides nucléiques modifiés

Publications (1)

Publication Number	Publication Date
CA2867489A1 true CA2867489A1 (fr)	2013-10-03

Family

ID=49261113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2867489A Abandoned CA2867489A1 (fr)	2012-03-30	2013-03-18	Procedes et composition permettant le sequencage d'acides nucleiques modifies

Country Status (4)

Country	Link
EP (1)	EP2831283A4 (fr)
AU (1)	AU2013240166A1 (fr)
CA (1)	CA2867489A1 (fr)
WO (1)	WO2013148400A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9290800B2 (en)	2013-03-15	2016-03-22	Pacific Biosciences Of California, Inc.	Targeted rolling circle amplification
MX392471B (es)	2013-11-17	2025-03-24	Quantum Si Inc	Sistema optico y chip de ensayo para sondear, detectar y analizar moleculas
CA2964937A1 (fr) *	2014-10-22	2016-04-28	Ibis Biosciences, Inc.	Analyse epigenomique bacterienne
US9618474B2 (en)	2014-12-18	2017-04-11	Edico Genome, Inc.	Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
EP3235010A4 (fr)	2014-12-18	2018-08-29	Agilome, Inc.	Transistor à effet de champ chimiquement sensible
US10006910B2 (en)	2014-12-18	2018-06-26	Agilome, Inc.	Chemically-sensitive field effect transistors, systems, and methods for manufacturing and using the same
US10020300B2 (en)	2014-12-18	2018-07-10	Agilome, Inc.	Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US9859394B2 (en)	2014-12-18	2018-01-02	Agilome, Inc.	Graphene FET devices, systems, and methods of using the same for sequencing nucleic acids
US9857328B2 (en)	2014-12-18	2018-01-02	Agilome, Inc.	Chemically-sensitive field effect transistors, systems and methods for manufacturing and using the same
WO2017201081A1 (fr)	2016-05-16	2017-11-23	Agilome, Inc.	Dispositifs à fet au graphène, systèmes et leurs méthodes d'utilisation pour le séquençage d'acides nucléiques
AU2017274412B2 (en) *	2016-06-01	2022-07-21	Quantum-Si Incorporated	Pulse caller and base caller
EP3366780B1 (fr) *	2017-02-23	2020-05-06	Siemens Healthcare GmbH	Analyse de séquence de molécules individuelles et de méthylation à très haute sensibilité pour analyse spécifique de tissus
EP3704265A4 (fr) *	2017-11-03	2021-09-29	Guardant Health, Inc.	Correction d'erreurs de séquence induites par désamination
MX2020007904A (es)	2018-01-26	2020-09-07	Quantum Si Inc	Llamado de pulso y base habilitado por maquina de aprendizaje para dispositivos de secuenciacion.
WO2019226689A1 (fr)	2018-05-22	2019-11-28	Axbio Inc.	Procédés, systèmes et compositions pour le séquençage d'acides nucléiques
WO2023055752A2 (fr)	2021-09-28	2023-04-06	Axbio Inc.	Procédés de traitement d'un échantillon d'acide nucléique et compositions associées
AU2023233577A1 (en) *	2022-03-17	2024-09-19	Regeneron Pharmaceuticals, Inc.	Methods for characterization of viral genome using base modifications
WO2024149841A1 (fr) *	2023-01-13	2024-07-18	F. Hoffmann-La Roche Ag	Détection de nucléobases modifiées dans des échantillons d'adn
CN117037904A (zh) *	2023-07-28	2023-11-10	浙江理工大学	一种基于图像的dna甲基化位点识别方法
CN118658521B (zh) *	2024-08-20	2024-11-15	嘉应学院	一种用于鱼类的基因数据智能分析方法及系统

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874239A (en)	1993-07-30	1999-02-23	Affymax Technologies N.V.	Biotinylation of proteins
US5795782A (en)	1995-03-17	1998-08-18	President & Fellows Of Harvard College	Characterization of individual polymer molecules based on monomer-interface interactions
EP1105529B2 (fr)	1998-07-30	2013-05-29	Illumina Cambridge Limited	Biomolecules en rangees et leur utilisation dans une procedure de sequencage
US7056661B2 (en)	1999-05-19	2006-06-06	Cornell Research Foundation, Inc.	Method for sequencing nucleic acid molecules
US6917726B2 (en)	2001-09-27	2005-07-12	Cornell Research Foundation, Inc.	Zero-mode clad waveguides for performing spectroscopy with confined effective observation volumes
WO2005014506A2 (fr)	2003-08-06	2005-02-17	Department Of Science & Technology (Dst)	Procede de fabrication d'un engrais a liberation biologique d'un micro-element nutritif anionique sous forme de molybdene
US20060046258A1 (en) *	2004-02-27	2006-03-02	Lapidus Stanley N	Applications of single molecule sequencing
US7399614B2 (en)	2004-06-30	2008-07-15	Applera Corporation	5-methylcytosine detection, compositions and methods therefor
WO2006044078A2 (fr)	2004-09-17	2006-04-27	Pacific Biosciences Of California, Inc.	Appareil et procede d'analyse de molecules
US7170050B2 (en)	2004-09-17	2007-01-30	Pacific Biosciences Of California, Inc.	Apparatus and methods for optical analysis of molecules
US7805081B2 (en)	2005-08-11	2010-09-28	Pacific Biosciences Of California, Inc.	Methods and systems for monitoring multiple optical signals from a single source
US7405281B2 (en)	2005-09-29	2008-07-29	Pacific Biosciences Of California, Inc.	Fluorescent nucleotide analogs and uses therefor
CA2622872A1 (fr)	2005-09-30	2007-04-12	Pacific Biosciences Of California, Inc.	Surfaces reactives, substrats et procedes de production et d'utilisation correspondants
US7998717B2 (en)	2005-12-02	2011-08-16	Pacific Biosciences Of California, Inc.	Mitigation of photodamage in analytical reactions
CA2633524A1 (fr)	2005-12-22	2007-07-05	Pacific Biosciences Of California, Inc.	Polymerases permettant d'incorporer des analogues de nucleotides
CA2662521C (fr)	2006-09-01	2016-08-09	Pacific Biosciences Of California, Inc.	Substrats, systemes et procedes d'analyse de materiaux
US20080277595A1 (en)	2007-05-10	2008-11-13	Pacific Biosciences Of California, Inc.	Highly multiplexed confocal detection systems and methods of using same
CA2689626C (fr) *	2007-06-06	2016-10-25	Pacific Biosciences Of California, Inc.	Methodes et procedes pour identifier des bases dans des procedes d'incorporation en fonction de la sequence
JP2010534474A (ja)	2007-07-26	2010-11-11	パシフィックバイオサイエンシーズオブカリフォルニア，インコーポレイテッド	分子冗長配列決定
US8652781B2 (en)	2008-02-12	2014-02-18	Pacific Biosciences Of California, Inc.	Cognate sampling kinetics
WO2009102470A2 (fr)	2008-02-12	2009-08-20	Pacific Biosciences Of California, Inc.	Compositions et procédés utilisables dans des réactions analytiques
US7968702B2 (en)	2008-03-13	2011-06-28	Pacific Biosciences Of California, Inc.	Labeled reactants and their uses
US7973146B2 (en)	2008-03-26	2011-07-05	Pacific Biosciences Of California, Inc.	Engineered fluorescent dye labeled nucleotide analogs for DNA sequencing
CN102084001B (zh)	2008-03-28	2015-03-18	加利福尼亚太平洋生物科学股份有限公司	用于核酸测序的组合物和方法
US8236499B2 (en)	2008-03-28	2012-08-07	Pacific Biosciences Of California, Inc.	Methods and compositions for nucleic acid sample preparation
US8143030B2 (en)	2008-09-24	2012-03-27	Pacific Biosciences Of California, Inc.	Intermittent detection during analytical reactions
WO2009145818A1 (fr) *	2008-03-31	2009-12-03	Pacific Biosciences Of California, Inc	Procédés et compositions de charge de molécule individuelle
AU2009251883B2 (en)	2008-03-31	2014-09-11	Pacific Biosciences Of California, Inc.	Generation of modified polymerases for improved accuracy in single molecule sequencing
CA2974241C (fr)	2008-09-16	2020-01-07	Pacific Biosciences Of California, Inc.	Substrats et systemes optiques et leurs procedes d'utilisation
US8481264B2 (en)	2008-09-19	2013-07-09	Pacific Biosciences Of California, Inc.	Immobilized nucleic acid complexes for sequence analysis
WO2010059235A2 (fr)	2008-11-20	2010-05-27	Pacific Biosciences Of California, Inc.	Algorithmes de détermination de séquence
US9175338B2 (en) *	2008-12-11	2015-11-03	Pacific Biosciences Of California, Inc.	Methods for identifying nucleic acid modifications
EP2370598B1 (fr) *	2008-12-11	2017-02-15	Pacific Biosciences Of California, Inc.	Classification de matrices d'acides nucléiques
JP5439822B2 (ja)	2009-01-15	2014-03-12	独立行政法人物質・材料研究機構	Ｎｉ基単結晶超合金
US9017937B1 (en)	2009-04-10	2015-04-28	Pacific Biosciences Of California, Inc.	Nanopore sequencing using ratiometric impedance
AU2010245304B2 (en)	2009-04-27	2015-06-04	Pacific Biosciences Of California, Inc.	Real-time sequencing methods and systems
WO2011103421A1 (fr) *	2010-02-18	2011-08-25	Shuber Anthony P	Compositions et méthodes pour le traitement du cancer
US9165109B2 (en)	2010-02-24	2015-10-20	Pacific Biosciences Of California, Inc.	Sequence assembly and consensus sequence determination
US20130138358A1 (en)	2010-02-24	2013-05-30	Pacific Biosciences Of California, Inc.	Algorithms for sequence determination

2013
- 2013-03-18 AU AU2013240166A patent/AU2013240166A1/en not_active Abandoned
- 2013-03-18 CA CA2867489A patent/CA2867489A1/fr not_active Abandoned
- 2013-03-18 EP EP13769322.2A patent/EP2831283A4/fr not_active Withdrawn
- 2013-03-18 WO PCT/US2013/032816 patent/WO2013148400A1/fr not_active Ceased

Also Published As

Publication number	Publication date
EP2831283A4 (fr)	2015-11-04
EP2831283A1 (fr)	2015-02-04
AU2013240166A1 (en)	2014-10-30
WO2013148400A1 (fr)	2013-10-03

Publication	Publication Date	Title
US10590484B2 (en)	2020-03-17	Methods and compositions for sequencing modified nucleic acids
CA2867489A1 (fr)	2013-10-03	Procedes et composition permettant le sequencage d'acides nucleiques modifies
US9175348B2 (en)	2015-11-03	Identification of 5-methyl-C in nucleic acid templates
CA2746632C (fr)	2020-06-30	Classification des acides nucleiques modifies
US9951383B2 (en)	2018-04-24	Methods of sequencing and identifying the position of a modified base in a nucleic acid
RU2754038C2 (ru)	2021-08-25	Способы амплификации днк для сохранения статуса метилирования
CN101233240A (zh)	2008-07-30	与质量分析结合的甲基化特异性扩增产物的碱基特异性切割
US11844666B2 (en)	2023-12-19	Classification of nucleic acid templates
US9909170B2 (en)	2018-03-06	Method for multiplexed nucleic acid patch polymerase chain reaction
US20220307077A1 (en)	2022-09-29	Conservative concurrent evaluation of dna modifications

Legal Events

Date	Code	Title	Description
2019-04-30	FZDE	Dead	Effective date: 20190319